Exogenous PTX3 is a promising potential therapeutic agent against CMV infection, both alone (Bozza et al., 2006) and in combination with Thymosin alpha-1 (Patent: use of thymosin alpha-1, alone and in combination with PTX3 or Ganciclovir, for the treatment of cytomegalovirus infection). This evidence concerns the gene PTMA and cytomegalovirus infection.